For Release at 6:00am EST JULY 16, 2003

NEWS – NEWS – NEWS

A/C DIAGNOSTICS UNIT OF ANTICANCER, INC., RECEIVES FDA CLEARANCE FOR HOMOCYSTEINE TEST

The A/C Diagnostics unit of AntiCancer, Inc., has received FDA clearance to market its A/C Enzymatic Homocysteine Assay. The new homocysteine assay uses a genetically-engineered enzyme specific for homocysteine. The assay will be able to serve the need for widespread testing for homocysteine, a risk factor for cardiovascular and other diseases. “The simplicity of the test, enables an economical price structure for the test kit. This gives us the possibility for gaining a significant share of the homocysteine test market,” said Yuying Tan, Product Manager and lead researcher for the A/C Enzymatic Homocysteine Assay.

A/C Diagnostics is a unit of AntiCancer, Inc., developing diagnostic tests based on specific recombinant enzymes. Other tests based on recombinant enzymes also being developed by A/C Diagnostics include vitamin B₆ and the amino acid cysteine, both associated with cardiovascular and other diseases.

AntiCancer, Inc., founded in 1984 and located in San Diego, is also developing new drugs for cancer based on genetic engineering and targeting cancer specific metabolic defects. The company markets clinically-relevant mouse models of metastatic cancer for cancer drug discovery and evaluation. The company is also developing gene therapy for cancer and for diseases of the hair follicle.

For more information, contact Charlene M. Cooper.

Fax: (858) 268-4175 OR E-mail: all@anticancer.com

7/15/03